Keywords: update, viracept, progress, agouron, protease, inhibitor, nelfinavir
Update On Viracept Progress
Article | 27 May 1996
- Agouron's protease inhibitor Viracept (nelfinavir mesylate) in combination with Bristol-Myers Squibb's Zerit (stavudine) can reduce viral load by 98%, according to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
